메뉴 건너뛰기




Volumn 16, Issue 9, 2015, Pages 1005-1018

Health state utilities associated with attributes of treatments for hepatitis C

Author keywords

Cost utility; Hepatitis C; Time horizon; Time trade off; Treatment process utility; Utility

Indexed keywords

ANTIVIRUS AGENT;

EID: 84947493707     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0649-6     Document Type: Article
Times cited : (38)

References (106)
  • 2
    • 84947502296 scopus 로고    scopus 로고
    • Management of Hepatitis C: (2002)
    • Management of Hepatitis C: (2002). http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
  • 3
    • 84869988183 scopus 로고    scopus 로고
    • The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States
    • COI: 1:STN:280:DC%2BC2c%2FlvVWhsg%3D%3D, PID: 23177279
    • Ward, J.W.: The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin. Liver Dis. 17, 1–11 (2013)
    • (2013) Clin. Liver Dis. , vol.17 , pp. 1-11
    • Ward, J.W.1
  • 4
    • 84947502297 scopus 로고    scopus 로고
    • Hepatitis C FAQs for the Public
    • Hepatitis C FAQs for the Public. http://www.cdc.gov/hepatitis/C/cFAQ.htm
  • 5
    • 0029894579 scopus 로고    scopus 로고
    • The natural history of chronic hepatitis C infection
    • COI: 1:STN:280:DyaK28znsFGrtQ%3D%3D, PID: 8781898
    • Strader, D.B., Seeff, L.B.: The natural history of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol. 8, 324–328 (1996)
    • (1996) Eur. J. Gastroenterol. Hepatol. , vol.8 , pp. 324-328
    • Strader, D.B.1    Seeff, L.B.2
  • 6
    • 74549128529 scopus 로고    scopus 로고
    • Epidemiology of hepatitis B and C viruses: a global overview
    • PID: 20123436
    • Te, H.S., Jensen, D.M.: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14, 1–21, vii (2010)
    • (2010) Clin Liver Dis , vol.14 , pp. 1-21
    • Te, H.S.1    Jensen, D.M.2
  • 7
    • 84857683435 scopus 로고    scopus 로고
    • Current status and future directions in the management of chronic hepatitis C
    • PID: 22385500
    • Aman, W., Mousa, S., Shiha, G., Mousa, S.A.: Current status and future directions in the management of chronic hepatitis C. Virol. J 9, 57 (2012)
    • (2012) Virol. J , vol.9 , pp. 57
    • Aman, W.1    Mousa, S.2    Shiha, G.3    Mousa, S.A.4
  • 8
    • 0030928695 scopus 로고    scopus 로고
    • Hepatitis C: the clinical spectrum of disease
    • COI: 1:STN:280:DyaK2svkvFWruw%3D%3D, PID: 9305658
    • Hoofnagle, J.H.: Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S–20S (1997)
    • (1997) Hepatology , vol.26 , pp. 15-20
    • Hoofnagle, J.H.1
  • 12
    • 77955481506 scopus 로고    scopus 로고
    • Hepatitis C virus infection and risk of cancer: a population-based cohort study
    • PID: 20865115
    • Omland, L.H., Farkas, D.K., Jepsen, P., Obel, N., Pedersen, L.: Hepatitis C virus infection and risk of cancer: a population-based cohort study. Clin. Epidemiol. 2, 179–186 (2010)
    • (2010) Clin. Epidemiol. , vol.2 , pp. 179-186
    • Omland, L.H.1    Farkas, D.K.2    Jepsen, P.3    Obel, N.4    Pedersen, L.5
  • 15
    • 84993709368 scopus 로고    scopus 로고
    • New agents for the treatment of hepatitis C in patients co-infected with HIV
    • PID: 25165545
    • Munteanu, D.I., Rockstroh, J.K.: New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther. Adv. Infect. Dis. 1, 71–80 (2013)
    • (2013) Ther. Adv. Infect. Dis. , vol.1 , pp. 71-80
    • Munteanu, D.I.1    Rockstroh, J.K.2
  • 16
    • 84873580144 scopus 로고    scopus 로고
    • Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials
    • COI: 1:CAS:528:DC%2BC3sXhs1entLg%3D, PID: 23369368
    • Sitole, M., Silva, M., Spooner, L., Comee, M.K., Malloy, M.: Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin. Ther. 35, 190–197 (2013)
    • (2013) Clin. Ther. , vol.35 , pp. 190-197
    • Sitole, M.1    Silva, M.2    Spooner, L.3    Comee, M.K.4    Malloy, M.5
  • 17
    • 84879141644 scopus 로고    scopus 로고
    • Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review
    • PID: 23556044
    • Bota, S., Sporea, I., Sirli, R., Popescu, A., Neghina, A.M., Danila, M., Strain, M.: Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J. Hepatol. 5, 120–126 (2013)
    • (2013) World J. Hepatol. , vol.5 , pp. 120-126
    • Bota, S.1    Sporea, I.2    Sirli, R.3    Popescu, A.4    Neghina, A.M.5    Danila, M.6    Strain, M.7
  • 18
    • 84874596467 scopus 로고    scopus 로고
    • Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes
    • PID: 23420134
    • Manos, M.M., Ho, C.K., Murphy, R.C., Shvachko, V.A.: Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient 6, 23–34 (2013)
    • (2013) Patient , vol.6 , pp. 23-34
    • Manos, M.M.1    Ho, C.K.2    Murphy, R.C.3    Shvachko, V.A.4
  • 19
    • 84874101281 scopus 로고    scopus 로고
    • Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review
    • PID: 23550100
    • Modabbernia, A., Poustchi, H., Malekzadeh, R.: Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat. Mon. 13, e8340 (2013)
    • (2013) Hepat. Mon. , vol.13 , pp. 8340
    • Modabbernia, A.1    Poustchi, H.2    Malekzadeh, R.3
  • 20
    • 84862738738 scopus 로고    scopus 로고
    • Management of side-effects
    • PID: 22248698
    • Rosa, I.: Management of side-effects. Clin. Res. Hepatol. Gastroenterol. 35(Suppl 2), S69–S74 (2011)
    • (2011) Clin. Res. Hepatol. Gastroenterol. , vol.35 , pp. 69-74
    • Rosa, I.1
  • 21
    • 77954746102 scopus 로고    scopus 로고
    • Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry
    • COI: 1:CAS:528:DC%2BC3cXhtV2nt7zJ, PID: 20500732
    • Alam, I., Stainbrook, T., Cecil, B., Kistler, K.D.: Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment. Pharmacol. Ther. 32, 535–542 (2010)
    • (2010) Aliment. Pharmacol. Ther. , vol.32 , pp. 535-542
    • Alam, I.1    Stainbrook, T.2    Cecil, B.3    Kistler, K.D.4
  • 22
    • 79960964116 scopus 로고    scopus 로고
    • Patient preferences and assessment of likely adherence to hepatitis C virus treatment
    • COI: 1:STN:280:DC%2BC3MjhsFCnug%3D%3D, PID: 20579276
    • Brett Hauber, A., Mohamed, A.F., Beam, C., Medjedovic, J., Mauskopf, J.: Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J. Viral Hepat. 18, 619–627 (2011)
    • (2011) J. Viral Hepat. , vol.18 , pp. 619-627
    • Brett Hauber, A.1    Mohamed, A.F.2    Beam, C.3    Medjedovic, J.4    Mauskopf, J.5
  • 23
    • 84881239177 scopus 로고    scopus 로고
    • Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran
    • PID: 24032043
    • Ravi, S., Nasiri Toosi, M., Karimzadeh, I., Ahadi-Barzoki, M., Khalili, H.: Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran. Hepat. Mon. 13, e11038 (2013)
    • (2013) Hepat. Mon. , vol.13 , pp. 11038
    • Ravi, S.1    Nasiri Toosi, M.2    Karimzadeh, I.3    Ahadi-Barzoki, M.4    Khalili, H.5
  • 29
    • 84876286638 scopus 로고    scopus 로고
    • Hepatitis C virus therapy update 2013
    • PID: 23563981
    • Casey, L.C., Lee, W.M.: Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 29, 243–249 (2013)
    • (2013) Curr Opin Gastroenterol , vol.29 , pp. 243-249
    • Casey, L.C.1    Lee, W.M.2
  • 30
    • 84899970077 scopus 로고    scopus 로고
    • The rapid evolution of treatment strategies for hepatitis C
    • COI: 1:CAS:528:DC%2BC2cXnslGitL4%3D, PID: 24732866
    • Muir, A.J.: The rapid evolution of treatment strategies for hepatitis C. Am. J. Gastroenterol. 109, 628–635 (2014)
    • (2014) Am. J. Gastroenterol. , vol.109 , pp. 628-635
    • Muir, A.J.1
  • 31
    • 84897441948 scopus 로고    scopus 로고
    • Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C
    • PID: 24603445
    • Brogan, A.J., Talbird, S.E., Thompson, J.R., Miller, J.D., Rubin, J., Deniz, B.: Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS ONE 9, e90295 (2014)
    • (2014) PLoS ONE , vol.9 , pp. 90295
    • Brogan, A.J.1    Talbird, S.E.2    Thompson, J.R.3    Miller, J.D.4    Rubin, J.5    Deniz, B.6
  • 32
    • 84884549621 scopus 로고    scopus 로고
    • Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons
    • Martin, N.K., Hickman, M., Miners, A., Hutchinson, S.J., Taylor, A., Vickerman, P.: Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3, e003153 (2013)
    • (2013) BMJ Open , vol.e003153 , pp. 3
    • Martin, N.K.1    Hickman, M.2    Miners, A.3    Hutchinson, S.J.4    Taylor, A.5    Vickerman, P.6
  • 34
    • 84873427421 scopus 로고    scopus 로고
    • Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
    • PID: 23329380
    • McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11, 53–63 (2013)
    • (2013) Appl. Health Econ. Health Policy , vol.11 , pp. 53-63
    • McEwan, P.1    Kim, R.2    Yuan, Y.3
  • 35
    • 67649839932 scopus 로고    scopus 로고
    • Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines
    • PID: 19485429
    • Siebert, U., Sroczynski, G., Aidelsburger, P., Rossol, S., Wasem, J., Manns, M.P., McHutchison, J.G., Wong, J.B.: Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 27, 341–354 (2009)
    • (2009) Pharmacoeconomics , vol.27 , pp. 341-354
    • Siebert, U.1    Sroczynski, G.2    Aidelsburger, P.3    Rossol, S.4    Wasem, J.5    Manns, M.P.6    McHutchison, J.G.7    Wong, J.B.8
  • 36
    • 0037372609 scopus 로고    scopus 로고
    • German hepatitis CMG, international hepatitis interventional therapy G: cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    • COI: 1:STN:280:DC%2BD3s%2FpsFyjtQ%3D%3D, PID: 12584228
    • Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B.M., Manns, M.P., McHutchison, J.G., Wong, J.B.: German hepatitis CMG, international hepatitis interventional therapy G: cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52, 425–432 (2003)
    • (2003) Gut , vol.52 , pp. 425-432
    • Siebert, U.1    Sroczynski, G.2    Rossol, S.3    Wasem, J.4    Ravens-Sieberer, U.5    Kurth, B.M.6    Manns, M.P.7    McHutchison, J.G.8    Wong, J.B.9
  • 37
    • 82955193770 scopus 로고    scopus 로고
    • Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C
    • PID: 22152176
    • Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14, 1068–1077 (2011)
    • (2011) Value Health , vol.14 , pp. 1068-1077
    • Townsend, R.1    McEwan, P.2    Kim, R.3    Yuan, Y.4
  • 38
    • 33747189558 scopus 로고    scopus 로고
    • Preference-based measures: utility and quality-adjusted life years
    • Fayers P, Hays R, (eds), Oxford University Press, New York
    • Feeny, D.: Preference-based measures: utility and quality-adjusted life years. In: Fayers, P., Hays, R. (eds.) Assessing quality of life in clinical trials, 2nd edn, pp. 405–431. Oxford University Press, New York (2005)
    • (2005) Assessing quality of life in clinical trials , pp. 405-431
    • Feeny, D.1
  • 39
    • 84875734849 scopus 로고    scopus 로고
    • Health utility measurement
    • Glied S, Smith P, (eds), Oxford University Press, New York
    • Rowen, D., Brazier, J.: Health utility measurement. In: Glied, S., Smith, P. (eds.) The Oxford Handbook of Health Economics, pp. 788–813. Oxford University Press, New York (2011)
    • (2011) The Oxford Handbook of Health Economics , pp. 788-813
    • Rowen, D.1    Brazier, J.2
  • 40
    • 47249161145 scopus 로고    scopus 로고
    • Health-state utilities in liver disease: a systematic review
    • McLernon, D.J., Dillon, J., Donnan, P.T.: Health-state utilities in liver disease: a systematic review. Med. Decis. Mak. 28, 582–592 (2008)
    • (2008) Med. Decis. Mak. , vol.28 , pp. 582-592
    • McLernon, D.J.1    Dillon, J.2    Donnan, P.T.3
  • 41
    • 8844221170 scopus 로고    scopus 로고
    • Health values of patients with chronic hepatitis C infection
    • PID: 15557419
    • Sherman, K.E., Sherman, S.N., Chenier, T., Tsevat, J.: Health values of patients with chronic hepatitis C infection. Arch. Intern. Med. 164, 2377–2382 (2004)
    • (2004) Arch. Intern. Med. , vol.164 , pp. 2377-2382
    • Sherman, K.E.1    Sherman, S.N.2    Chenier, T.3    Tsevat, J.4
  • 42
    • 84891685662 scopus 로고    scopus 로고
    • Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation
    • COI: 1:STN:280:DC%2BD28zjtVOhsQ%3D%3D
    • Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., U. k. Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10, 1–113 (2006)
    • (2006) Health Technol. Assess. , vol.10 , pp. 1-113
    • Wright, M.1    Grieve, R.2    Roberts, J.3    Main, J.4    Thomas, H.C.5
  • 43
    • 0035120575 scopus 로고    scopus 로고
    • Assessment of utilities and health-related quality of life in patients with chronic liver disease
    • COI: 1:STN:280:DC%2BD3M7ot12lsg%3D%3D, PID: 11232711
    • Younossi, Z.M., Boparai, N., McCormick, M., Price, L.L., Guyatt, G.: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am. J. Gastroenterol. 96, 579–583 (2001)
    • (2001) Am. J. Gastroenterol. , vol.96 , pp. 579-583
    • Younossi, Z.M.1    Boparai, N.2    McCormick, M.3    Price, L.L.4    Guyatt, G.5
  • 45
    • 85027938643 scopus 로고    scopus 로고
    • Impact of treatment attributes of peginterferon for hepatitis C on quality of life and treatment preference
    • Kerr, C., Lloyd, A., Ali, S., Gore, C., Tyas, D.A.: Impact of treatment attributes of peginterferon for hepatitis C on quality of life and treatment preference. Health Outcomes Res. Med. 3, e153–e167 (2012)
    • (2012) Health Outcomes Res. Med. , vol.3 , pp. 153-167
    • Kerr, C.1    Lloyd, A.2    Ali, S.3    Gore, C.4    Tyas, D.A.5
  • 46
    • 84873840448 scopus 로고    scopus 로고
    • Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
    • COI: 1:CAS:528:DC%2BC3sXhvVymuro%3D, PID: 23159839
    • Cooper, C., Lester, R., Thorlund, K., Druyts, E., El Khoury, A.C., Yaya, S., Mills, E.J.: Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 106, 153–163 (2013)
    • (2013) QJM , vol.106 , pp. 153-163
    • Cooper, C.1    Lester, R.2    Thorlund, K.3    Druyts, E.4    El Khoury, A.C.5    Yaya, S.6    Mills, E.J.7
  • 47
    • 84876789373 scopus 로고    scopus 로고
    • Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population
    • COI: 1:CAS:528:DC%2BC3sXnvFahsL4%3D, PID: 23627926
    • Jin, Y.J., Lee, J.W., Lee, J.I., Park, S.H., Park, C.K., Kim, Y.S., Jeong, S.H., Kim, Y.S., Kim, J.H., Hwang, S.G., et al.: Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 13, 74 (2013)
    • (2013) BMC Gastroenterol. , vol.13 , pp. 74
    • Jin, Y.J.1    Lee, J.W.2    Lee, J.I.3    Park, S.H.4    Park, C.K.5    Kim, Y.S.6    Jeong, S.H.7    Kim, Y.S.8    Kim, J.H.9    Hwang, S.G.10
  • 48
    • 84947502298 scopus 로고    scopus 로고
    • EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. EuroQol Group Executive Office ed., Version 4.0 edition. Rotterdam, The Netherlands: EuroQol Group, pp
    • Rabin, R., Oemar, M., Oppe, M.: EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. EuroQol Group Executive Office ed., Version 4.0 edition. Rotterdam, The Netherlands: EuroQol Group, pp. 1–21 (2011)
    • (2011) 1–21
    • Rabin, R.1    Oemar, M.2    Oppe, M.3
  • 49
    • 3042545839 scopus 로고    scopus 로고
    • The Health Utilities Index (HUI): concepts, measurement properties and applications
    • PID: 14613568
    • Horsman, J., Furlong, W., Feeny, D., Torrance, G.: The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes 1, 54 (2003)
    • (2003) Health Qual. Life Outcomes , vol.1 , pp. 54
    • Horsman, J.1    Furlong, W.2    Feeny, D.3    Torrance, G.4
  • 50
    • 39449087063 scopus 로고    scopus 로고
    • Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens
    • COI: 1:CAS:528:DC%2BD1cXksFCju7w%3D, PID: 18282016
    • Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., Marchant, N.: Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 26, 217–234 (2008)
    • (2008) Pharmacoeconomics , vol.26 , pp. 217-234
    • Chancellor, J.1    Aballea, S.2    Lawrence, A.3    Sheldon, R.4    Cure, S.5    Plun-Favreau, J.6    Marchant, N.7
  • 51
    • 79958062820 scopus 로고    scopus 로고
    • Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
    • PID: 20224930
    • Boye, K.S., Matza, L.S., Walter, K.N., Van Brunt, K., Palsgrove, A.C., Tynan, A.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12, 219–230 (2011)
    • (2011) Eur. J. Health Econ. , vol.12 , pp. 219-230
    • Boye, K.S.1    Matza, L.S.2    Walter, K.N.3    Van Brunt, K.4    Palsgrove, A.C.5    Tynan, A.6
  • 52
    • 84859138459 scopus 로고    scopus 로고
    • Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study
    • PID: 22472127
    • Osborne, R.H., Dalton, A., Hertel, J., Schrover, R., Smith, D.K.: Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual. Life Outcomes 10, 35 (2012)
    • (2012) Health Qual. Life Outcomes , vol.10 , pp. 35
    • Osborne, R.H.1    Dalton, A.2    Hertel, J.3    Schrover, R.4    Smith, D.K.5
  • 53
    • 84868459981 scopus 로고    scopus 로고
    • Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Support
    • COI: 1:STN:280:DC%2BC38vjs1Kmuw%3D%3D
    • Teuffel, O., Cheng, S., Ethier, M.C., Diorio, C., Martino, J., Mayo, C., Wing, R., Sung, L., Alibhai, S.M.: Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Support. Care Cancer 20, 2755–2764 (2012)
    • (2012) Care Cancer , vol.20 , pp. 2755-2764
    • Teuffel, O.1    Cheng, S.2    Ethier, M.C.3    Diorio, C.4    Martino, J.5    Mayo, C.6    Wing, R.7    Sung, L.8    Alibhai, S.M.9
  • 54
    • 0036016989 scopus 로고    scopus 로고
    • Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis
    • PID: 12180075
    • Feeny, D., Townsend, M., Furlong, W., Tomkins, D.J., Robinson, G.E., Torrance, G.W., Mohide, P.T., Wang, Q.: Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis. Genet Test 6, 39–46 (2002)
    • (2002) Genet Test , vol.6 , pp. 39-46
    • Feeny, D.1    Townsend, M.2    Furlong, W.3    Tomkins, D.J.4    Robinson, G.E.5    Torrance, G.W.6    Mohide, P.T.7    Wang, Q.8
  • 58
    • 84881078908 scopus 로고    scopus 로고
    • Telaprevir: changing the standard of care of chronic hepatitis C
    • COI: 1:STN:280:DC%2BC3svptlSjsg%3D%3D, PID: 23525057
    • Rajani, A.K., Ravindra, B.K., Dkhar, S.A.: Telaprevir: changing the standard of care of chronic hepatitis C. J. Postgrad. Med. 59, 42–47 (2013)
    • (2013) J. Postgrad. Med. , vol.59 , pp. 42-47
    • Rajani, A.K.1    Ravindra, B.K.2    Dkhar, S.A.3
  • 59
    • 84876738261 scopus 로고    scopus 로고
    • Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
    • PID: 23490868
    • Teixeira, R., Nascimento Yde, A., Crespo, D.: Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz. J. Infect. Dis. 17, 194–204 (2013)
    • (2013) Braz. J. Infect. Dis. , vol.17 , pp. 194-204
    • Teixeira, R.1    Nascimento Yde, A.2    Crespo, D.3
  • 61
    • 0030560819 scopus 로고    scopus 로고
    • Modelling valuations for health states: the effect of duration
    • COI: 1:STN:280:DyaK2s%2FntFKhsw%3D%3D, PID: 10162421
    • Dolan, P.: Modelling valuations for health states: the effect of duration. Health Policy 38, 189–203 (1996)
    • (1996) Health Policy , vol.38 , pp. 189-203
    • Dolan, P.1
  • 62
    • 0031279593 scopus 로고    scopus 로고
    • Modeling valuations for EuroQol health states
    • COI: 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D, PID: 9366889
    • Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)
    • (1997) Med. Care , vol.35 , pp. 1095-1108
    • Dolan, P.1
  • 64
    • 34347324128 scopus 로고    scopus 로고
    • Interferon-based treatment of chronic hepatitis C
    • COI: 1:CAS:528:DC%2BD2sXnsFKrurc%3D, PID: 17570576
    • Souvignet, C., Lejeune, O., Trepo, C.: Interferon-based treatment of chronic hepatitis C. Biochimie 89, 894–898 (2007)
    • (2007) Biochimie , vol.89 , pp. 894-898
    • Souvignet, C.1    Lejeune, O.2    Trepo, C.3
  • 65
    • 84947502299 scopus 로고    scopus 로고
    • Janssen-Cilag Pharmaceuticals: Summary of product characteristics: Incivo 375 mg film-coated tablets telaprevir. In Labelling, Package Leaflet. Latina, Italy: European Public Assessment Reports (EPAR)
    • Janssen-Cilag Pharmaceuticals: Summary of product characteristics: Incivo 375 mg film-coated tablets telaprevir. In Labelling, Package Leaflet. Latina, Italy: European Public Assessment Reports (EPAR)
  • 66
    • 84879664119 scopus 로고    scopus 로고
    • Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions
    • COI: 1:CAS:528:DC%2BC3sXhvVSmt7nN, PID: 23553423
    • Kiang, T.K., Wilby, K.J., Ensom, M.H.: Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin. Pharmacokinet. 52, 487–510 (2013)
    • (2013) Clin. Pharmacokinet. , vol.52 , pp. 487-510
    • Kiang, T.K.1    Wilby, K.J.2    Ensom, M.H.3
  • 67
    • 84868649787 scopus 로고    scopus 로고
    • Boceprevir in chronic hepatitis C infection: a perspective review
    • COI: 1:CAS:528:DC%2BC38Xptlyrur0%3D, PID: 23251772
    • Ascione, A.: Boceprevir in chronic hepatitis C infection: a perspective review. Ther. Adv. Chronic Dis. 3, 113–121 (2012)
    • (2012) Ther. Adv. Chronic Dis. , vol.3 , pp. 113-121
    • Ascione, A.1
  • 68
    • 84878799939 scopus 로고    scopus 로고
    • Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
    • COI: 1:CAS:528:DC%2BC3sXhtF2qtL7F, PID: 23710734
    • Gordon, S.C., Yoshida, E.M., Lawitz, E.J., Bacon, B.R., Sulkowski, M.S., Davis, M., Poordad, F., Bronowicki, J.P., Esteban, R., Sniukiene, V., et al.: Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment. Pharmacol. Ther. 38, 16–27 (2013)
    • (2013) Aliment. Pharmacol. Ther. , vol.38 , pp. 16-27
    • Gordon, S.C.1    Yoshida, E.M.2    Lawitz, E.J.3    Bacon, B.R.4    Sulkowski, M.S.5    Davis, M.6    Poordad, F.7    Bronowicki, J.P.8    Esteban, R.9    Sniukiene, V.10
  • 69
    • 84947502300 scopus 로고    scopus 로고
    • Summary of product characteristics: victrelis 200 mg hard capsules boceprevir. In Labelling, Package Leaflet. Hertfordshire, UK: European Public Assessment Reports (EPAR)
    • Merck Sharp & Dohme: Summary of product characteristics: victrelis 200 mg hard capsules boceprevir. In Labelling, Package Leaflet. Hertfordshire, UK: European Public Assessment Reports (EPAR). Last updated on eMC 11 September 2014
    • (2014) Last updated on eMC , pp. 11
  • 70
    • 84872565980 scopus 로고    scopus 로고
    • Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review
    • PID: 23437439
    • Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E.B., Fu, R.: Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann. Intern. Med. 158, 114–123 (2013)
    • (2013) Ann. Intern. Med. , vol.158 , pp. 114-123
    • Chou, R.1    Hartung, D.2    Rahman, B.3    Wasson, N.4    Cottrell, E.B.5    Fu, R.6
  • 72
    • 84947502301 scopus 로고    scopus 로고
    • SP (Brinny) Company: Summary of product characteristics: IntronA 3 million IU/0.5 ml solution for injection or infusion interferon alfa-2b. In Labelling, Package Leaflet. County Cork, Ireland: European Public Assessment Reports (EPAR)
    • SP (Brinny) Company: Summary of product characteristics: IntronA 3 million IU/0.5 ml solution for injection or infusion interferon alfa-2b. In Labelling, Package Leaflet. County Cork, Ireland: European Public Assessment Reports (EPAR)
  • 73
    • 84947502302 scopus 로고    scopus 로고
    • Penn Pharmaceutical Services: Summary of product characteristics: Ribavirin Mylan 200 mg hard capsules In Labelling, Package Leaflet. Gwent County, UK: European Public Assessment Reports (EPAR)
    • Penn Pharmaceutical Services: Summary of product characteristics: Ribavirin Mylan 200 mg hard capsules In Labelling, Package Leaflet. Gwent County, UK: European Public Assessment Reports (EPAR)
  • 74
    • 51149089137 scopus 로고    scopus 로고
    • Valuing health states for use in cost-effectiveness analysis
    • PID: 18767897
    • Brazier, J.: Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 26, 769–779 (2008)
    • (2008) Pharmacoeconomics , vol.26 , pp. 769-779
    • Brazier, J.1
  • 76
    • 84947502303 scopus 로고    scopus 로고
    • London, UK: National Institute for Health and Clinical Excellence
    • NICE (National Institute for Health and Clinical Excellence): Process and methods guides: guide to the methods of technology appraisal 2013. London, UK: National Institute for Health and Clinical Excellence (2013)
    • (2013) Process and methods guides: guide to the methods of technology appraisal , vol.2013
  • 77
    • 84947502304 scopus 로고    scopus 로고
    • Guidelines for preparing submissions to PBAC, Version 4.3.2
    • PBAC (Pharmaceutical Benefits Advisory Committee): Guidelines for preparing submissions to PBAC, Version 4.3.2. PBAC (2008)
    • (2008) PBAC
  • 78
    • 0030102792 scopus 로고    scopus 로고
    • The time trade-off method: results from a general population study
    • COI: 1:STN:280:DyaK28zhtVWjtg%3D%3D, PID: 8733106
    • Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5, 141–154 (1996)
    • (1996) Health Econ. , vol.5 , pp. 141-154
    • Dolan, P.1    Gudex, C.2    Kind, P.3    Williams, A.4
  • 79
    • 12344257034 scopus 로고    scopus 로고
    • Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies
    • PID: 15386674
    • Arnesen, T., Trommald, M.: Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies. Health Econ. 14, 39–53 (2005)
    • (2005) Health Econ. , vol.14 , pp. 39-53
    • Arnesen, T.1    Trommald, M.2
  • 80
    • 49949098352 scopus 로고    scopus 로고
    • A community-based study of acne-related health preferences in adolescents
    • PID: 18711070
    • Chen, C.L., Kuppermann, M., Caughey, A.B., Zane, L.T.: A community-based study of acne-related health preferences in adolescents. Arch. Dermatol. 144, 988–994 (2008)
    • (2008) Arch. Dermatol. , vol.144 , pp. 988-994
    • Chen, C.L.1    Kuppermann, M.2    Caughey, A.B.3    Zane, L.T.4
  • 81
    • 84859979197 scopus 로고    scopus 로고
    • Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom
    • PID: 21988666
    • Guest, J.F., Naik, N., Sladkevicius, E., Coombs, J., Gray, E.J.: Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk. Lymphoma 53, 928–933 (2012)
    • (2012) Leuk. Lymphoma , vol.53 , pp. 928-933
    • Guest, J.F.1    Naik, N.2    Sladkevicius, E.3    Coombs, J.4    Gray, E.J.5
  • 84
    • 38349084979 scopus 로고    scopus 로고
    • Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study
    • COI: 1:STN:280:DC%2BD1c%2FmtFWlsQ%3D%3D, PID: 18070214
    • Schmitt, J., Meurer, M., Klon, M., Frick, K.D.: Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br. J. Dermatol. 158, 351–359 (2008)
    • (2008) Br. J. Dermatol. , vol.158 , pp. 351-359
    • Schmitt, J.1    Meurer, M.2    Klon, M.3    Frick, K.D.4
  • 87
    • 84881162364 scopus 로고    scopus 로고
    • Incorporating process utility into quality adjusted life years: a systematic review of empirical studies
    • PID: 23771494
    • Brennan, V.K., Dixon, S.: Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics 31, 677–691 (2013)
    • (2013) Pharmacoeconomics , vol.31 , pp. 677-691
    • Brennan, V.K.1    Dixon, S.2
  • 88
  • 89
    • 0033840246 scopus 로고    scopus 로고
    • Development and testing of a utility measure for major, unipolar depression (McSad)
    • COI: 1:STN:280:DC%2BD3cvlsFahsA%3D%3D, PID: 10981211
    • Bennett, K.J., Torrance, G.W., Boyle, M.H., Guscott, R., Moran, L.A.: Development and testing of a utility measure for major, unipolar depression (McSad). Qual. Life Res. 9, 109–120 (2000)
    • (2000) Qual. Life Res. , vol.9 , pp. 109-120
    • Bennett, K.J.1    Torrance, G.W.2    Boyle, M.H.3    Guscott, R.4    Moran, L.A.5
  • 90
    • 0031938365 scopus 로고    scopus 로고
    • Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications
    • COI: 1:STN:280:DyaK1c7lsV2rtQ%3D%3D, PID: 9495599
    • Revicki, D.A., Wood, M.: Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J. Affect. Disord. 48, 25–36 (1998)
    • (1998) J. Affect. Disord. , vol.48 , pp. 25-36
    • Revicki, D.A.1    Wood, M.2
  • 91
    • 4243147176 scopus 로고    scopus 로고
    • Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder
    • PID: 15128456
    • Sapin, C., Fantino, B., Nowicki, M.L., Kind, P.: Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2, 20 (2004)
    • (2004) Health Qual. Life Outcomes , vol.2 , pp. 20
    • Sapin, C.1    Fantino, B.2    Nowicki, M.L.3    Kind, P.4
  • 92
    • 33947591945 scopus 로고    scopus 로고
    • Health-related quality of life measured with EQ-5D in patients treated for depression in primary care
    • PID: 17391424
    • Sobocki, P., Ekman, M., Agren, H., Krakau, I., Runeson, B., Martensson, B., Jonsson, B.: Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 10, 153–160 (2007)
    • (2007) Value Health , vol.10 , pp. 153-160
    • Sobocki, P.1    Ekman, M.2    Agren, H.3    Krakau, I.4    Runeson, B.5    Martensson, B.6    Jonsson, B.7
  • 93
    • 0034917145 scopus 로고    scopus 로고
    • Introducing economic and quality of life measurements into clinical studies
    • COI: 1:STN:280:DC%2BD3MvksFWqsA%3D%3D, PID: 11491193
    • Drummond, M.: Introducing economic and quality of life measurements into clinical studies. Ann. Med. 33, 344–349 (2001)
    • (2001) Ann. Med. , vol.33 , pp. 344-349
    • Drummond, M.1
  • 94
    • 20144374806 scopus 로고    scopus 로고
    • The minimally clinically important difference in generic utility-based measures
    • PID: 17136968
    • Kaplan, R.M.: The minimally clinically important difference in generic utility-based measures. COPD 2, 91–97 (2005)
    • (2005) COPD , vol.2 , pp. 91-97
    • Kaplan, R.M.1
  • 95
    • 77950282183 scopus 로고    scopus 로고
    • Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments
    • PID: 20355266
    • Luo, N., Johnson, J., Coons, S.J.: Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med. Care 48, 365–371 (2010)
    • (2010) Med. Care , vol.48 , pp. 365-371
    • Luo, N.1    Johnson, J.2    Coons, S.J.3
  • 96
    • 12344320344 scopus 로고    scopus 로고
    • A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis
    • PID: 15652688
    • Marra, C.A., Woolcott, J.C., Kopec, J.A., Shojania, K., Offer, R., Brazier, J.E., Esdaile, J.M., Anis, A.H.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)
    • (2005) Soc. Sci. Med. , vol.60 , pp. 1571-1582
    • Marra, C.A.1    Woolcott, J.C.2    Kopec, J.A.3    Shojania, K.4    Offer, R.5    Brazier, J.E.6    Esdaile, J.M.7    Anis, A.H.8
  • 97
    • 39749097822 scopus 로고    scopus 로고
    • Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
    • PID: 18154669
    • Pickard, A.S., Neary, M.P., Cella, D.: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5, 70 (2007)
    • (2007) Health Qual Life Outcomes , vol.5 , pp. 70
    • Pickard, A.S.1    Neary, M.P.2    Cella, D.3
  • 98
    • 0003662748 scopus 로고
    • Guide to design and development of health-state utility instrumentation. Hamilton, ON: McMaster University
    • Furlong, W., Feeny, D.H., Torrance, G.W., et al.: Guide to design and development of health-state utility instrumentation. Hamilton, ON: McMaster University, Report No. 90-99 (1990)
    • (1990) Report No , pp. 90-99
    • Furlong, W.1    Feeny, D.H.2    Torrance, G.W.3
  • 99
    • 84863061002 scopus 로고    scopus 로고
    • Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury
    • PID: 22289233
    • Lin, M.R., Yu, W.Y., Wang, S.C.: Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch. Phys. Med. Rehabil. 93, 245–252 (2012)
    • (2012) Arch. Phys. Med. Rehabil. , vol.93 , pp. 245-252
    • Lin, M.R.1    Yu, W.Y.2    Wang, S.C.3
  • 100
    • 84947502305 scopus 로고    scopus 로고
    • Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., McDaniel, K., Jordan, J., Devine, K., Davies, E.: The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In ISPOR 15th Annual European Congress; November 3–7, 2012, Berlin, Germany (2012)
    • Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., McDaniel, K., Jordan, J., Devine, K., Davies, E.: The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In ISPOR 15th Annual European Congress; November 3–7, 2012, Berlin, Germany (2012)
  • 101
    • 0028979652 scopus 로고
    • The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off
    • COI: 1:STN:280:DyaK28%2FhtVSisg%3D%3D, PID: 7561982
    • Stiggelbout, A.M., Kiebert, G.M., Kievit, J., Leer, J.W., Habbema, J.D., De Haes, J.C.: The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J. Clin. Epidemiol. 48, 1207–1214 (1995)
    • (1995) J. Clin. Epidemiol. , vol.48 , pp. 1207-1214
    • Stiggelbout, A.M.1    Kiebert, G.M.2    Kievit, J.3    Leer, J.W.4    Habbema, J.D.5    De Haes, J.C.6
  • 102
    • 67149139335 scopus 로고    scopus 로고
    • The influence of subjective life expectancy on health state valuations using a 10 year TTO
    • PID: 18702082
    • van Nooten, F.E., Koolman, X., Brouwer, W.B.: The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ. 18, 549–558 (2009)
    • (2009) Health Econ. , vol.18 , pp. 549-558
    • van Nooten, F.E.1    Koolman, X.2    Brouwer, W.B.3
  • 103
    • 84900360613 scopus 로고    scopus 로고
    • Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO
    • van Nooten, F.E., Koolman, X., Busschbach, J.J., Brouwer, W.B.: Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO. Qual. Life Res. 23, 377–384 (2013)
    • (2013) Qual. Life Res , vol.23 , pp. 377-384
    • van Nooten, F.E.1    Koolman, X.2    Busschbach, J.J.3    Brouwer, W.B.4
  • 104
    • 0027450184 scopus 로고
    • Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer
    • COI: 1:STN:280:DyaK3s7mtlyiuw%3D%3D, PID: 8433117
    • Gerard, K., Dobson, M., Hall, J.: Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J. Clin. Epidemiol. 46, 77–84 (1993)
    • (1993) J. Clin. Epidemiol. , vol.46 , pp. 77-84
    • Gerard, K.1    Dobson, M.2    Hall, J.3
  • 105
    • 84856607845 scopus 로고    scopus 로고
    • It’s all in the name, or is it? The impact of labeling on health state values
    • Rowen, D., Brazier, J., Tsuchiya, A., Young, T., Ibbotson, R.: It’s all in the name, or is it? The impact of labeling on health state values. Med. Decis. Mak. 32, 31–40 (2012)
    • (2012) Med. Decis. Mak. , vol.32 , pp. 31-40
    • Rowen, D.1    Brazier, J.2    Tsuchiya, A.3    Young, T.4    Ibbotson, R.5
  • 106
    • 0018155086 scopus 로고
    • The utility of different health states as perceived by the general public
    • COI: 1:STN:280:DyaE1M%2FovVyltw%3D%3D, PID: 730825
    • Sackett, D.L., Torrance, G.W.: The utility of different health states as perceived by the general public. J. Chronic. Dis. 31, 697–704 (1978)
    • (1978) J. Chronic. Dis. , vol.31 , pp. 697-704
    • Sackett, D.L.1    Torrance, G.W.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.